Showing 4041-4050 of 6590 results for "".
- Almirall and Athenex Form Strategic Partnership for Treatment of AKshttps://practicaldermatology.com/news/almirall-and-athenex-form-strategic-partnership-for-treatment-of-aks/2457957/Almirall, S.A and Athenex, Inc. recently formed a partnership to further develop and commercialize KX2-391 for the treatment of actinic keratosis (AK) and other skin conditions. Subject to the terms and conditions of the license agreement, Athenex will grant to Almirall an exclusive
- FDA Grants Extended Clearance of the Describe Patch for Tattoo Removalhttps://practicaldermatology.com/news/fda-grants-extended-clearance-of-the-describe-patch-for-tattoo-removal/2457960/Merz North America’s DESCRIBE® PFD Patch is now cleared by the Food and Drug Administration (FDA) for all commonly used lasers for tattoo removal. The new FDA clearance also extends the shelf life of the Patch from two years
- Parent-supplied Photos May Allow Pediatric Derms to Make Virtual Diagnoseshttps://practicaldermatology.com/news/parent-supplied-photos-may-allow-pediatric-derms-to-make-virtual-diagnoses/2457968/Parent-supplied photos taken via smartphone cameras can allow pediatric dermatologists to make a diagnosis without an office visit in many cases, new research shows. This finding, which appear in JAMA Dermatology, suggest that direct-to-patient dermatology can accurate
- Long-Term Use of Lilly's Taltz Shows Efficacy Improvements in PsA for Patients with Prior Inadequate Response or Intolerance to TNF Inhibitorshttps://practicaldermatology.com/news/long-term-use-of-lillys-taltz-shows-efficacy-improvements-in-psa-for-patients-with-prior-inadequate-response-or-intolerance-to-tnf-inhibitors/2457980/Patients with active psoriatic arthritis (PsA) treated with Taltz (ixekizumab), who were previously intolerant or had inadequate responses to TNF inhibitors, showed improvements in the signs and symptoms of PsA across treatment groups for up to 52 weeks, according to Eli Lilly and Company. Interi
- NRS Introduces New Standard Classification and Pathophysiology of Rosaceahttps://practicaldermatology.com/news/nrs-introduces-new-standard-classification-and-pathophysiology-of-rosacea/2457979/The National Rosacea Society (NRS) is introducing a new standard classification and pathophysiology of rosacea. The updated system appears in the Journal of the American Academy of Dermatology. Devel
- Novan Plans to Complete Development of SB204 Acne Candidate via Third Party Funding and Executionhttps://practicaldermatology.com/news/novan-plans-to-complete-development-of-sb204-acne-candidate-via-third-party-funding-and-execution/2457981/Novan, Inc., has agreed in principle to a business structure that would enable further development and advancement of SB204 for the treatment of acne vulgaris via third party financing and third party execution of one additional Phase 3 pivotal trial that is required before the filing of a New Dr
- Study: PsO, RA Patients Prescribed Similar Drugs, But PsO Patients Face Higher Liver Disease Riskhttps://practicaldermatology.com/news/study-pso-ra-patients-prescribed-similar-drugs-yet-pso-patients-face-higher-liver-disease-risk/2457987/Compared to controls, patients with psoriasis (PsO) are at higher risk for serious liver disease than patients with rheumatoid arthritis, reports a in the Journal of Investigative Dermatology from researchers a
- Dermatomyositis Breakthrough? Drug reduces disease burden in patients with skin-predominant DMhttps://practicaldermatology.com/news/dermatomyositis-breakthrough-drug-reduces-disease-burden-in-patients-with-skin-predominant-dm/2457990/A new treatment for dermatomyositis (DM) may reduce the severity of the disease in patients whose DM was resistant to other therapies. As part of a randomized, double-blind study conducted at the Perelman School of Medicine at the University of Pennsyl
- Prospective Cosmetic Surgery Patients Often In The Dark About Financing Optionshttps://practicaldermatology.com/news/prospective-cosmetic-surgery-patients-in-the-dark-about-financing-options/2457994/Fully 76 percent of prospective patients are unaware of financing options for cosmetic procedures, yet almost two-thirds of them would be more likely to book if they were aware that financing was a viable option, according to a survey by
- Sun Dermatology Launches Absorica Tracker App to Help Patients Track Progresshttps://practicaldermatology.com/news/sun-dermatology-launches-absorica-tracker-app-to-help-patients-track-progress/2457999/Sun Pharma launched an Absorica Tracker App to help patients get the most out of their treatment. The easy-to-use interface is designed to help users to monitor their progress with Absorica (isotretinoin) treatment with features like medication and appointment reminders, monthly tips and checklis